⚠️ Auto-extracted by Claude on 2026-06-13 — closed-access / paywalled; no PMC record; full text not available. Claims sourced exclusively from verified metadata and the verbatim abstract. Do NOT rely on any quantitative findings from this page until a full-text verification pass is completed against the primary source. gap/no-fulltext-access
Suryadevara et al. 2026 — Charting human cellular senescence in aging and disease (SenNet Perspective)
Cell, vol. 189, issue 12, pages 3501–3505 (11 June 2026). doi:10.1016/j.cell.2026.05.028 · PMID:42276030. Published by the NIH SenNet Consortium with corresponding authors including P. Robbins and R. Fan.
Access: Closed-access; not available via PubMed Central; no OA version confirmed at time of seeding. gap/no-fulltext-access
Conflict of interest (disclosed): P. Robbins holds University of Minnesota patents on senotherapeutic compounds and is co-founder of Itasca Therapeutics (a senotherapeutics company). Other conflicts not confirmed from abstract alone.
What this paper is
This is a Review / Perspective article — not a primary data paper. It introduces a conceptual and technical framework for systematically mapping senescent cell heterogeneity across human tissues. The article is associated with the NIH SenNet (Cellular Senescence Network) Consortium, a large multi-institution effort to build a human cross-tissue atlas of cellular senescence.
As a Perspective, it does not independently report primary experimental endpoints such as blood biomarker panels, specific tissue cell counts, or clinical correlations. Those data come from companion SenNet data papers (see Future seeding leads below).
Core framework introduced: “Senotypes”
The central conceptual contribution, per the abstract, is the framing of cellular senescence as not a single uniform state but as a collection of diverse, tissue-specific cell states that the authors call “senotypes.”
Key claims supportable from the abstract:
- Senescent cells comprise heterogeneous states that emerge across human tissues during aging and disease — not a single canonical arrested-cell phenotype.
- Integrating single-cell multi-omics, spatial multi-omics, and AI-driven analyses enables systematic mapping of this heterogeneity (“senotypes”), revealing tissue-specific programs and microenvironmental interactions.
- This framework provides a foundation for biomarker discovery (senotype-specific markers, not pan-senescence markers only) and for development of targeted senotherapeutic strategies (senotype-matched rather than pan-senolytic approaches).
The “senotype” term unifies prior observations of cell-type-specific SASP composition (see sasp § SASP composition) and cell-type-specific anti-apoptotic programs (SCAPs — see cellular-senescence § Anti-apoptotic programs (SCAPs)) into an atlas-scale, multi-omic, spatially resolved framework applicable to human tissues in vivo.
Significance for the wiki
This Perspective is the field’s most direct framing of senescent cell heterogeneity as a systematic, mappable phenomenon in human tissues (rather than inferred from in-vitro models or rodent studies). Its key import for the wiki:
- Senotype as a term to adopt — prior wiki content uses “cell-type-specific SASP” and “cell-type-specific SCAPs”; this paper argues those are instances of a broader senotype architecture that is also shaped by microenvironmental context within a given tissue, not just cell identity.
- Single-cell + spatial multi-omics as the necessary methodology — the claim is that conventional bulk-tissue or single-marker approaches (p16+, SA-β-gal, SASP panel) are insufficient to capture senotype heterogeneity; sc/sn RNA-seq + spatial transcriptomics + AI are the enabling platform.
- Targeted senotherapeutics — the therapeutic implication is that senolytic / senomorphic drug development should be senotype-matched, not pan-targeted; this parallels the SCAP-matching argument in senolytics but extends it to include microenvironmental context and spatial information.
Future seeding leads (NOT seeded here — companion data papers)
The broader SenNet effort includes companion data papers that are cited in press coverage and should be seeded separately when accessible. These are not results reported in this Perspective and must not be attributed to this paper:
- Cross-tissue atlas data paper — specific cell populations, senotype identities, and tissue-specific senescence programs quantified across organs (SenNet Consortium).
- Blood senescence biomarkers — circulating biomarkers predicting kidney disease, frailty, and diabetes risk (Basisty, Gorospe lab contributions; reported in companion data papers per press coverage, not in this Perspective).
- SenLect — a reported genetically-encoded system to purify/isolate senescent cells (companion preprint; description from title only — verify before seeding).
- ATP6V1B2+ persistent senescent cell population — a reported cell population identified in the SenNet atlas data.
Each of these should be seeded from primary data papers once accessible, NOT from this Perspective.
Wiki home for the senotype concept
The primary atomic home for this framework is cellular-senescence — see § Senescent-cell heterogeneity and the senotype concept (added 2026-06-13). The senotype concept is a sub-aspect of cellular senescence with one citable source at time of seeding; a standalone senotype.md page is not yet warranted. Promote to atomic page when additional independent primary sources appear.
Cross-references
- cellular-senescence — primary atomic home for senotype framework
- sasp — SASP heterogeneity is one dimension of senotype variation
- senolytics — SCAP-matching argument; senotype-targeted therapy connects here
- senomorphics — senotype-targeted SASP suppression strategy
- hallmarks-of-aging — parent hallmark framework